TY - JOUR
T1 - Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
AU - Russo, Antonio
AU - Fulfaro, Fabio
AU - Zobel, Bruno Beomonte
AU - Silletta, Marianna
AU - Dicuonzo, Giordano
AU - Rocci, Laura
AU - Galluzzo, Sara
AU - Battistoni, Fabrizio
AU - Vincenzi, Bruno
AU - Adamo, Vincenzo
AU - Tonini, Giuseppe
AU - Santini, Daniele
PY - 2008
Y1 - 2008
N2 - Introduction: Magnesium plays a role in a large number of cellular metabolic reactions.Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transportin the kidney.We designed this trial to investigate if Mg2+ serum level modifications may be relatedwith clinical response andoutcome in advancedcolorectal cancer patients during treatment withcetuximab plus irinotecan.Experimental Design: Sixty-eight heavily pretreatedmetastatic colorectal cancer patients wereevaluatedfor Mg2+ serum levels at the following time points: before; 6 hours; and1, 7, 14, 21, 50,and92 days after the start of treatment.Results: Basal Mg2+ median levels were significantly decreased just 7 days after the firstanticancer infusion and progressively decreased from the 7th day onward, reaching the highestsignificance at the last time point (P < 0.0001).Twenty-five patients showeda reduction in medianMg2+ circulating levels of at least 20% within the 3rdweek after the first infusion. Patients withthis reduction showed a response rate of 64.0% versus 25.6% in the nonreduced Mg2+ group.The median time to progression was 6.0 versus 3.6 months in the reduced Mg2+ group andin thatwithout reduction, respectively (P < 0.0001). Overall survival was longer in patients with Mg2+reduction than in those without (10.7 versus 8.9 months).Conclusions: Our results confirm that cetuximab treatment may induce a reduction of Mg2+circulating levels andoffer the first evidence that Mg2+ reduction may represent a new predictivefactor of efficacy in advanced colorectal cancer patients treated with cetuximab plus irinotecan
AB - Introduction: Magnesium plays a role in a large number of cellular metabolic reactions.Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transportin the kidney.We designed this trial to investigate if Mg2+ serum level modifications may be relatedwith clinical response andoutcome in advancedcolorectal cancer patients during treatment withcetuximab plus irinotecan.Experimental Design: Sixty-eight heavily pretreatedmetastatic colorectal cancer patients wereevaluatedfor Mg2+ serum levels at the following time points: before; 6 hours; and1, 7, 14, 21, 50,and92 days after the start of treatment.Results: Basal Mg2+ median levels were significantly decreased just 7 days after the firstanticancer infusion and progressively decreased from the 7th day onward, reaching the highestsignificance at the last time point (P < 0.0001).Twenty-five patients showeda reduction in medianMg2+ circulating levels of at least 20% within the 3rdweek after the first infusion. Patients withthis reduction showed a response rate of 64.0% versus 25.6% in the nonreduced Mg2+ group.The median time to progression was 6.0 versus 3.6 months in the reduced Mg2+ group andin thatwithout reduction, respectively (P < 0.0001). Overall survival was longer in patients with Mg2+reduction than in those without (10.7 versus 8.9 months).Conclusions: Our results confirm that cetuximab treatment may induce a reduction of Mg2+circulating levels andoffer the first evidence that Mg2+ reduction may represent a new predictivefactor of efficacy in advanced colorectal cancer patients treated with cetuximab plus irinotecan
UR - http://hdl.handle.net/10447/42935
M3 - Article
SN - 1078-0432
VL - 14
SP - 4219
EP - 4224
JO - Clinical Cancer Research
JF - Clinical Cancer Research
ER -